Livanova Plc Stock Price, News & Analysis

LivaNova (Nasdaq: LIVN) has appointed Donald (Don) Zurbay to its Board of Directors, where he will serve on the Audit and Compliance Committee. Zurbay brings over 30 years of experience in finance, accounting, and strategy, most recently serving as President and CEO of Patterson Companies after being its CFO. He previously spent nearly 13 years at St. Jude Medical in various leadership roles, including CFO.

Zurbay currently serves on the Board of Directors at Sight Sciences, chairing its Audit Committee. He holds a bachelor's degree in business accounting from the University of Minnesota. With this appointment, the LivaNova Board now comprises 11 Directors.

LivaNova (Nasdaq: LIVN), a leading medical technology company, has announced its upcoming Investor Day scheduled for November 12, 2025, from 9 a.m. to 1 p.m. EST in New York City. The event will feature presentations from key executives, including CEO Vladimir Makatsaria and CFO Alex Shvartsburg, who will outline the company's strategic roadmap and growth initiatives.

The event will be accessible both in-person (requiring advance registration) and via webcast on the company's website. Presentation materials and a replay will be made available in the Investors section of LivaNova's website following the event.

LivaNova (Nasdaq: LIVN), a medical technology company, announced its leadership team's participation in two upcoming healthcare conferences. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will present business updates at the Baird 2025 Global Healthcare Conference on September 9 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 in New York City.

Both presentations will be accessible via webcast on the company's website, with replays available for 90 days after each event. Interested parties must register to attend the webcasts and should log on 10 minutes before the start time.

LivaNova (Nasdaq: LIVN) has launched its Essenz™ Perfusion System in China, marking a significant expansion in the world's second-largest market for heart-lung machines. The system, which received NMPA approval, has already supported over 100,000 patients globally since its February 2023 launch.

The Essenz system includes the next-generation heart-lung machine, Patient Monitor, and In-Line Blood Monitor, designed in collaboration with over 300 perfusionists worldwide. The launch is particularly significant given China's projected 185,000 adult and 23,500 pediatric extracorporeal circulation procedures in 2025, serving a market where approximately 330 million individuals are affected by cardiovascular disease.

LivaNova (Nasdaq: LIVN) reported strong Q2 2025 results and raised its full-year guidance. The company achieved revenue of $352.5 million, representing a 10.7% reported growth and 10.3% organic growth. Q2 2025 adjusted diluted EPS reached $1.05, up from $0.93 in Q2 2024.

The company's Cardiopulmonary segment grew 14.7% to $199.3 million, while Neuromodulation increased 6.2% to $151.7 million. LivaNova raised its 2025 guidance, now expecting revenue growth of 8.0-9.0% on a constant-currency basis and adjusted EPS of $3.70-$3.80.

Notable developments include initiating CMS reconsideration for VNS Therapy coverage in treatment-resistant depression and publishing positive long-term data for drug-resistant epilepsy treatment.

LivaNova (Nasdaq: LIVN), a leading medical technology company, has scheduled its second-quarter 2025 earnings conference call for August 6, 2025, at 1 p.m. London time (8 a.m. EDT). The company will release its Q2 2025 financial results before the call.

Investors can access the audiocast at www.livanova.com/events. For telephone access, U.S. participants should dial +1 833 470 1428, while international callers can use +1 929 526 1599 with access code 460430. A replay will be available on LivaNova's website for 90 days after the call.

LivaNova (LIVN) has announced the completion of its CORE-VNS study, demonstrating significant effectiveness of VNS Therapy for treating drug-resistant epilepsy (DRE) in both children and adults. The 36-month study, involving over 800 patients worldwide, showed remarkable seizure reduction rates. In children aged 4-18, focal impaired awareness motor seizures decreased by 87%, while focal to bilateral tonic-clonic seizures showed a 100% median reduction. Among all patients, including adults, 34% achieved complete freedom from focal impaired awareness motor seizures, with an 80% median reduction. Additionally, 49% reported complete freedom from focal to bilateral tonic-clonic seizures, with a 95% median reduction. The study maintained an impressive 82% patient retention rate and showed effectiveness as early as three months post-implantation, with continued improvements throughout the study period.

LivaNova (LIVN) has announced significant 24-month data from their CORE-VNS study published in Epilepsia, showing remarkable effectiveness of VNS Therapy in treating drug-resistant epilepsy (DRE). The study demonstrated a 77% median reduction in generalized tonic-clonic (GTC) seizures at 24 months, with 43% of participants achieving seizure freedom. The study involved patients with a median 10-year epilepsy duration, with 90% diagnosed before age 18. Notably, patients showed early response with 52% seizure reduction at 3 months. The study population had previously failed a median of six anti-seizure medications, with some trying up to 20 different treatments. The research included over 800 epilepsy patients worldwide, with 115 specifically having drug-resistant epilepsy and generalized seizures at baseline.

LivaNova (LIVN) has initiated the process with CMS to seek Medicare coverage reconsideration for VNS Therapy in treatment-resistant depression (TRD) patients. The company's request is supported by five critical peer-reviewed articles featuring RECOVER study data, along with strong 24-month clinical outcomes. The data shows VNS Therapy's durability, with 81.3% of patients maintaining benefits at 24 months, and response rates increasing from 40.2% at 12 months to 51.6% at 24 months. Additional analyses revealed 43% higher odds of meaningful improvement in suicidal ideation compared to the control group, with separation visible as early as three months. The RECOVER study, completed in March 2024, demonstrated that VNS Therapy improves symptoms, function, and quality of life in TRD patients who had previously failed multiple treatments, including ECT and TMS.